In few words

The MagenTa (Molecules-or metal-based Imaging N'Therapeutic Agents) team was created in September 2019 as a continuation of the SOMAB (Organometallic Probes for Biomedical Applications) team in order to porvide original markers and efficient analysis tools for biomedical applications with diagnostic and/or therapeutic purposes. 
MagenTa is pursuing its activities on the development of functional metal complexes that are stable in biological media, such as long-lived luminophores (europium, terbium, rhenium), contrast agents (gadolinium) or radiopharmaceuticals (technetium-99m, indium-111, rhenium-188, yttrium-90). The team is now interested in molecules called PhotoCORMs (Photochemically CO-Releasing Molecules) which allow the controlled production of CO in time period and space under the action of light. In addition, the team is expanding the range of complexing ligands developed so far to new multifunctional polyphenolic platforms. Their polyvalent character is currently being studied in the context of pathologies linked to oxidative stress.

from synthetic chemistry to medical imaging  in vitro et in vivo

  • Polyfonctionnal ligands synthesis  : multi-step synthesis, bioconjugation, Click to Chelate strategy
  • Synthesis and characterisation of mono or multi-metal complexes (lanthanides ions, pseudo-lanthanides and transition metals) solubles and stables in biological media and suitable to bioconjugation.
  • Evaluation and application of complexes as  luminescents bio-labelling (TR-FRET), contrastophores (MRI) and radiopharmaceuticals (diagnostic and internal vectorised radiotherapy).
  • Elaboration of multimodals probes to correlate several imaging modes.
  • Development of fluorescent dyes for use in the solid state and controlled preparation of nanoparticles.

Key words

Multi-step Synthesis , bifonctionnal chelates , macrocycles, metal complexes , bioconjugation, imaging,  fluorescent probes,  magnetic probes, radiopharmaceuticals,  bimodal probes, nanoparticules.

Our partnerships

  •  Cisbio Bioassays, Codolet, France (HTRF - sondes luminescentes lanthanidiques).
  • Pr. E. Borbas, Uppsala, Sweden (Collaboration Thèse de A. Perez De Heridia)
  • Pr L. Vander Elst, Mons, Belgium (new MRI contrast agents).
  • Dr N. Malek-Saied, Sidi Thabet, Tunisia (in vivo Evaluation of 99mTc radiopharmaceuticals).
  • Dr A. Erriguible, Université de Bordeaux (Nanoparticules)
  • Dr B. Delavaux-Nicot, LCC Toulouse (Electrochimie)
  • Dr C. Le Roux, GET Toulouse (Hybrides de talc synthétique)
  • Dr R. Métivier, Dr C. Allain, ENS Paris Saclay  (Photophysique)